Johnson & Johnson is leading the precision neuroscience revolution to reduce the burden and disability caused by serious nervous system disorders. Our goal is to deliver breakthrough solutions for people with neuropsychiatric, neurodegenerative, and neurological autoantibody-driven diseases. Our strategy harnesses scientific advances in four areas: human genetics, data science, biomarkers, and digital health. We leverage these advances to enable precision approaches for target and patient identification, target modulation and therapeutic focus. Building on our nearly seven-decade legacy in psychiatry, we are committed to making an impact for the over one billion people affected by diseases of the brain.